Cyfuse Biomedical K.K. (TYO:4892)
Japan
· Delayed Price · Currency is JPY 977.00
-5.00 (-0.51%)
Apr 28, 2025, 3:30 PM JST
Cyfuse Biomedical K.K. Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Cash & Equivalents | 3,052 | 3,873 | 4,437 | 2,413 | 2,072 | Upgrade
|
| Cash & Short-Term Investments | 3,052 | 3,873 | 4,437 | 2,413 | 2,072 | Upgrade
|
| Cash Growth | -21.20% | -12.71% | 83.88% | 16.46% | 10.32% | Upgrade
|
| Accounts Receivable | 20 | 17 | 13 | 57 | 19 | Upgrade
|
| Other Receivables | 43 | 32 | 56 | - | 17 | Upgrade
|
| Receivables | 63 | 49 | 69 | 57 | 36 | Upgrade
|
| Inventory | 55 | 46 | 40 | 61 | 21 | Upgrade
|
| Prepaid Expenses | 51 | 16 | 17 | 5 | 17 | Upgrade
|
| Other Current Assets | 19 | 3 | 2 | 22 | 5 | Upgrade
|
| Total Current Assets | 3,240 | 3,987 | 4,565 | 2,558 | 2,151 | Upgrade
|
| Property, Plant & Equipment | 141 | 169 | 189 | 27 | 32 | Upgrade
|
| Long-Term Investments | 131 | 53 | 55 | 55 | 5 | Upgrade
|
| Other Intangible Assets | 4 | 4 | 5 | 4 | 5 | Upgrade
|
| Other Long-Term Assets | 2 | 1 | 1 | 2 | 3 | Upgrade
|
| Total Assets | 3,518 | 4,214 | 4,815 | 2,646 | 2,196 | Upgrade
|
| Accounts Payable | 15 | 2 | 4 | 8 | - | Upgrade
|
| Accrued Expenses | 16 | 19 | 25 | 6 | 4 | Upgrade
|
| Short-Term Debt | 507 | 550 | 467 | 128 | 50 | Upgrade
|
| Current Portion of Long-Term Debt | 18 | 18 | 77 | 72 | 23 | Upgrade
|
| Current Portion of Leases | - | - | - | 8 | 16 | Upgrade
|
| Current Income Taxes Payable | 59 | 47 | 74 | 74 | 29 | Upgrade
|
| Current Unearned Revenue | 20 | 19 | 22 | 19 | 25 | Upgrade
|
| Other Current Liabilities | 13 | 11 | 13 | 71 | 59 | Upgrade
|
| Total Current Liabilities | 648 | 666 | 682 | 386 | 206 | Upgrade
|
| Long-Term Debt | 327 | 345 | 363 | 359 | 431 | Upgrade
|
| Long-Term Leases | - | - | - | - | 7 | Upgrade
|
| Other Long-Term Liabilities | 1 | 1 | 1 | 1 | 3 | Upgrade
|
| Total Liabilities | 976 | 1,012 | 1,046 | 746 | 647 | Upgrade
|
| Common Stock | 1,364 | 1,283 | 1,272 | 100 | 100 | Upgrade
|
| Additional Paid-In Capital | 3,986 | 3,905 | 3,893 | 2,721 | 2,618 | Upgrade
|
| Retained Earnings | -2,858 | -1,986 | -1,396 | -922 | -1,169 | Upgrade
|
| Comprehensive Income & Other | 50 | - | - | 1 | - | Upgrade
|
| Shareholders' Equity | 2,542 | 3,202 | 3,769 | 1,900 | 1,549 | Upgrade
|
| Total Liabilities & Equity | 3,518 | 4,214 | 4,815 | 2,646 | 2,196 | Upgrade
|
| Total Debt | 852 | 913 | 907 | 567 | 527 | Upgrade
|
| Net Cash (Debt) | 2,200 | 2,960 | 3,530 | 1,846 | 1,545 | Upgrade
|
| Net Cash Growth | -25.68% | -16.15% | 91.22% | 19.48% | -15.49% | Upgrade
|
| Net Cash Per Share | 273.27 | 378.89 | 1323.28 | 3688.31 | 3086.91 | Upgrade
|
| Filing Date Shares Outstanding | 8.14 | 7.83 | 6.44 | 0.5 | 0.5 | Upgrade
|
| Total Common Shares Outstanding | 8.14 | 7.83 | 6.44 | 0.5 | 0.5 | Upgrade
|
| Working Capital | 2,592 | 3,321 | 3,883 | 2,172 | 1,945 | Upgrade
|
| Book Value Per Share | 312.31 | 409.12 | 585.09 | 3796.20 | 3094.91 | Upgrade
|
| Tangible Book Value | 2,538 | 3,198 | 3,764 | 1,896 | 1,544 | Upgrade
|
| Tangible Book Value Per Share | 311.82 | 408.60 | 584.31 | 3788.21 | 3084.92 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.